Intravitreal Bevacizumab and Low Fluence Photodynamic Therapy

• Status: Completed
• Trial end date: 2009-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to report the treatment effect and safety of combined intravitreal bevacizumab (IVB) and photodynamic therapy (PDT) with verteporfin using a reduced (RF) light fluence rate, in choroidal neovascularization (CNV) secondary to pathologic myopia.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Second University of Naples; University of Campania "Luigi Vanvitelli"
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

• Myopic CNV, CNV leakage

Exclusion Criteria:

• CNV not associated with high myopia

• No activity of CNV